Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 4/20 | 0.53 |
| ▸ | RAF1 | P04049 | 4/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15573238 | 0.92 | DDR2 (0.64) | DDR2RAF1BRAFKDR | |
| SCHEMBL16990692 | 0.91 | DDR2 (0.52) | DDR2RAF1BRAFKDR | |
| SCHEMBL15574210 | 0.87 | DDR2 (0.68) | DDR2RAF1BRAFKDR | |
| SCHEMBL16990740 | 0.87 | DDR2 (0.55) | DDR2RAF1LMNASMN1; SMN2BRAF | |
| SCHEMBL15575289 | 0.87 | DDR2 (0.65) | DDR2RAF1LMNASMN1; SMN2BRAF | |
| SCHEMBL16990646 | 0.87 | DDR2 (0.51) | DDR2RAF1LMNASMN1; SMN2BRAF | |
| SCHEMBL16990734 | 0.86 | DDR2 (0.53) | DDR2RAF1CARM1PRMT6LMNA | |
| SCHEMBL16990681 | 0.86 | DDR2 (0.56) | DDR2RAF1BRAFKDRPPARG | |
| SCHEMBL16990663 | 0.86 | DDR2 (0.54) | DDR2RAF1CARM1PRMT6BRAF | |
| SCHEMBL16990671 | 0.84 | DDR2 (0.52) | DDR2RAF1LMNASMN1; SMN2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885RAF1 3072/4885CARM1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.